Responses
ePoster
EP991 Exceptional response with combined anti-hormone and MEK inhibitor therapy in a patient with hormone receptor-positive ovarian cancer and isolated KRAS alteration. Implications for a precision medicine strategy
Compose a Response to This Article
Other responses
No responses have been published for this article.